Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
netupitant metabolite + palonosetron
- Development stage
- Unknown
- Lead developer
- HK inno.N Corporation
- Modality
- Peptides, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
IN-A012 is a fixed-dose combination therapy consisting of an undisclosed netupitant metabolite and palonosetron. It is being developed by HK inno.N for the prevention and treatment of nausea and vomiting. The drug acts as both a neurokinin 1 (NK1) receptor antagonist (via the netupitant metabolite) and a serotonin 3 (5-HT3) receptor antagonist (via palonosetron), targeting two key pathways involved in emesis. As of early 2022, it had reached preregistration status in South Korea for intravenous use in adults, with completed phase I trials demonstrating bioequivalence to Akynzeo capsules[4][3][5].
- Other names
- netupitant metabolite/palonosetron
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)TACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on netupitant metabolite + palonosetron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on netupitant metabolite + palonosetron.